Sankar, K.; Bryant, A.K.; Strohbehn, G.W.; Zhao, L.; Elliott, D.; Moghanaki, D.; Kelley, M.J.; Ramnath, N.; Green, M.D.
Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. Cancers 2022, 14, 614.
https://doi.org/10.3390/cancers14030614
AMA Style
Sankar K, Bryant AK, Strohbehn GW, Zhao L, Elliott D, Moghanaki D, Kelley MJ, Ramnath N, Green MD.
Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. Cancers. 2022; 14(3):614.
https://doi.org/10.3390/cancers14030614
Chicago/Turabian Style
Sankar, Kamya, Alex K. Bryant, Garth W. Strohbehn, Lili Zhao, David Elliott, Drew Moghanaki, Michael J. Kelley, Nithya Ramnath, and Michael D. Green.
2022. "Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer" Cancers 14, no. 3: 614.
https://doi.org/10.3390/cancers14030614
APA Style
Sankar, K., Bryant, A. K., Strohbehn, G. W., Zhao, L., Elliott, D., Moghanaki, D., Kelley, M. J., Ramnath, N., & Green, M. D.
(2022). Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. Cancers, 14(3), 614.
https://doi.org/10.3390/cancers14030614